OverviewChartNewsTraderScreen

Soc. Generale Knock-Out AMD 17.05.../  DE000SW7X356  /

Frankfurt Zert./SG
5/15/2024  7:52:22 PM Chg.-0.590 Bid8:08:55 PM Ask8:08:55 PM Underlying Strike price Expiration date Option type
6.560EUR -8.25% 6.520
Bid Size: 70,000		 6.530
Ask Size: 70,000		 Advanced Micro Devic... 230.00 USD 5/17/2024 Put
GlobeNewswire 5/14 UNITY Biotechnology, Inc. Reports First Quarter 2024 Financial Results and Business Updates
GlobeNewswire 5/14 AMD Announces Upcoming Events for the Financial Community
GlobeNewswire 5/14 Apellis Pharmaceuticals Refinances Existing Debt with Up to $475 Million Non-Dilutive Credit Facilit...
GlobeNewswire 5/14 Belite Bio Reports First-Quarter 2024 Financial Results and Provides Corporate Update
GlobeNewswire 5/13 Outlook Therapeutics® Announces UK Submission of Marketing Authorization Application (MAA) for ONS-5...
GlobeNewswire 5/13 AMD Remains the Partner of Choice for World’s Fastest and Most Efficient High Performance Computing ...
GlobeNewswire 5/9 Clearside Biomedical Announces First Quarter 2024 Financial Results and Provides Corporate Update
GlobeNewswire 5/9 Adverum Biotechnologies Reports First Quarter 2024 Financial Results and Provides Pipeline Highlight...
GlobeNewswire 5/9 4DMT Reports First Quarter 2024 Financial Results and Operational Highlights
GlobeNewswire 5/8 Alkeus Pharmaceuticals Announces Positive Interim Results Demonstrating No Signs of Disease Progress...
GlobeNewswire 5/8 Therini Bio Announces Positive Preclinical Data Supporting the Development of THN391 in Neurodegener...
GlobeNewswire 5/8 AMD Receives IEEE 2024 Corporate Innovation Award for Leadership in Chiplet Design for High-Performa...
GlobeNewswire 5/8 Belite Bio to Host Webcast on May 14, 2024, to Discuss First Quarter 2024 Financial Results
GlobeNewswire 5/8 EyePoint Pharmaceuticals Reports First Quarter 2024 Financial Results and Highlights Recent Corporat...
GlobeNewswire 5/7 Ocular Therapeutix™ Reports First Quarter 2024 Results
GlobeNewswire 5/7 Optiver Chooses AMD Enterprise Portfolio to Power its Data Center Modernization, Enabling New Era of...
GlobeNewswire 5/7 Apellis Pharmaceuticals Reports First Quarter 2024 Financial Results
GlobeNewswire 5/7 Ocular Therapeutix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire 5/6 Important Advances in Oxurion's R&D Program on Geographic Atrophy secondary to AMD
GlobeNewswire 5/6 Belite Bio to Participate in Key Opinion Leader Webinar to Discuss Unmet Needs In Stargardt Disease ...
GlobeNewswire 5/6 Belite Bio Presents Additional Analysis from Phase 2 Study of Tinlarebant in Stargardt Disease at th...
GlobeNewswire 5/6 Ocular Therapeutix™ to Present at Two Upcoming Investor Conferences
GlobeNewswire 5/6 EyePoint Pharmaceuticals Announces Topline Data from the Phase 2 PAVIA Trial of DURAVYU™ in Non-Prol...
GlobeNewswire 5/3 Ocular Therapeutix™ To Present at Two Ophthalmology Meetings, May 4-9, 2024
GlobeNewswire 5/3 YieldMax™ ETFs Announces Monthly Distributions on CONY (109.51%), MSTY (103.22%), NFLY (67.74%), SQY...